The recent data published by the staff in clinical research jobs at Pfizer and Bristol-Myers Squibb (BMS) is reported to have shown an explicit comparison of the benefits posed by the venous thromboembolism (VTE) drug apixaban compared to a leading rival drug.

The drug apixaban was being developed by the Pfizer and BMS as part of a global collaborative agreement underwent in 2007.

The recent phase III trial carried under the same showed the drug outpacing Sanofi-aventis' enoxaparin when it comes to their efficacy in lowering the incidence of venous thromboembolism (VTE) among patients undergoing elective total hip replacement surgery.

The results fetched by the trial were certainly robust, while outlining the beneficial nature of apixaban's convenient oral administration, said study’s lead author Dr. Michael Rud Lassen of the Hoersholm Hospital in Copenhagen.

It is claimed that apixaban, which is prescribed as an oral drug, was witnessed to be capable enough to pose these advantages, in addition to extending a comparable rate of major and clinically relevant non-major bleeding to the control drug.

Besides, the drug is also being studied to serve as a treatment for preventing strokes among patients surviving with atrial fibrillation.